Biotech Financing Roundup: Where the Money's At

There's a perceived transatlantic divide when it comes to biotechnology financing. European firms, the conventional wisdom goes, lack VC the support of their North American counterparts and thus are at an inherent disadvantage. But an analysis of 2004's VC financing trends shows that on average, European biotechs have pulled in respectable Series A and Series B rounds--later stage financing is another story.